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A new method using Raman 
spectroscopy for in vivo targeted 
brain cancer tissue biopsy





cancer with> in situ
Most solid cancers are discovered by conventional imaging techniques such as computed tomography (CT), mag-
netic resonance imaging (MRI), positron emission tomography (PET), and ultrasound (US). While these images 
characterize the location(s) and anatomical relationships of the cancer, most of them have limitations in terms 
of tumor grading and molecular characterization. Consequently, direct sampling for histological, molecular, and 
genomic characterisation is required for diagnosis and treatment planning. The quality of the tissue obtained for 
analysis is thus of vital importance to guide the clinical trajectory. Furthermore, as targeted therapies are known 
to cause imaging changes that appear to represent cancer progression, but are in fact only imaging changes caused 
by the treatments, oncology teams require high quality tumor sampling during and post-treatment in order to 
make correct treatment decisions1. As the use of these new therapies becomes more common the need for new 
and more informed tissue sampling approaches are needed.
To aid tumor targeting, biopsies are performed using approaches guided by conventional imaging such as 
US, CT, and MRI. Since these imaging techniques do not provide the user information regarding the nature of 
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the tissue prior to harvesting, and the precision of lesion targeting may be compromised by tissue shifts between 
the time of the imaging session and procedure or during the procedure, poor quality sampling often occurs. For 
example, the prostate cancer detection rate is only 40–45% at initial biopsy2–4. Similarly, the diagnostic yield 
of lung cancer biopsies varies from 42 to 100%. Importantly, non-diagnostic samples in brain cancer biopsies 
leading to repeat procedure occurs in up to 24% of cases5–7, and diagnostic errors still occur in 10–30% of cases8. 
For each pass of a biopsy needle there is an associated risk of hemorrhage and infection that can negatively affect 
patient outcomes6,9–12.
Current approaches to reduce the risk of poor quality sampling include intraoperative sample analysis based 
on histological processing such as tissue smears and frozen tissue sections, or harvesting multiple samples to 
increase the likelihood of a diagnostic sample. These approaches are resource intensive as they require 20–30 min-
utes for each sample to be processed and analysed thereby lengthening the duration of the procedure. Moreover, 
this analysis does not provide molecular information. The addition of real time molecular tissue characteriza-
tion capabilities to guide biopsy needle insertion and tissue collection can enhance the information provided to 
surgeons and interventionalists prior to sampling thereby improving the rate of high quality diagnostic yields. 
Informed tissue sampling also reduces patient risk by limiting the number of samples collected and reducing the 
rate of repeat procedures.
A strategy for real time informed cancer needle biopsy is to interrogate the tissue using optical techniques 
in situ prior to collection. This interrogation can provide the user with online feedback regarding the molecular 
nature of the tissue to confirm the targeting site, characterise the presence of cancer, avoid injury to major blood 
vessels, and avoid sampling necrotic tissue or tumor regions that do not represent the pathology. Optical tech-
niques have been developed for this purpose, including the use of the metabolic fluorescent biomarker protopor-
phyrin (Pp) IX that is endogenously synthesized in tumor cells following administration of 5-aminolevulenic 
acid. The red PpIX fluorescence could then be used to guide the insertion of a needle biopsy, as demonstrated 
clinically in brain on ex vivo biopsy tissue and in vivo in mouse models13–15. However, the technique requires 
the use of a contrast agent, which presents issues in terms of clinical practicality and tumor sensitivity. Optical 
coherence tomography (OCT) is also investigated for the guidance of needle biopsies, for applications in breast, 
prostate and lung cancer16–20. Recently, a RS probe that fits inside the bore of a hypodermic needle was developed 
for lymph-node biopsy guidance21,22. Although these are impressive advances, OCT has yet to show it’s ability to 
detect cancer in vivo.
In the past our group has developed Raman spectroscopy instruments for surgical guidance, demonstrating in 
vivo fingerprint (FP) Raman Spectroscopy (RS) can distinguish between normal brain, tumor tissue and necrosis 
with accuracies upwards of 90% in patients for grade 2–4 gliomas or metastasis associated with lung, colon and 
skin cancer cells23–28. The majority of biomedical RS studies have used near-infrared illumination and spectral 
detection in the 500–2000 cm−1 range29–33, commonly referred to as the fingerprint (FP) region, since it is rich 
in biochemical information associated with vibrational bonds of proteins, lipids, nucleic acids and amino acids. 
The high wavenumber (HWN) region, from about 2000 to 4000 cm−1, contains information relating to e.g. CH-, 
OH- and NH- stretching modes. High wavenumber shifts have been found to discriminate different types of brain 
tissue ex vivo, including cortex and white matter34,35. Stimulated Raman scattering (SRS) microscopy in the HWN 
regime has been used to differentiate tumors from normal brain in vivo in mice bearing intracranial glioblastoma 
xenografts27.
Here, we are presenting the development and preliminary validation of a new integrated biopsy system that 
provides in situ cancer characterization using spontaneous Raman spectroscopy. The device is in the form of an 
integrated Raman probe, engineered into a commercial biopsy system, with minimal disruption to the surgical 
workflow. First, a small-scale animal study is presented demonstrating that the novel optical needle can measure 
deep brain Raman spectra and collect tissue samples at the same location. Secondly, an in vivo human validation 
study is presented to demonstrate -during brain cancer resection surgeries- that a HWN RS intraoperative probe 
can accurately detect cancer tissue in situ. This sets the stage for the clinical translation of this optical molecular 
imaging method for high quality and safe targeted cancer biopsy.
We have developed an instru-
ment that can provide, rapidly and with minimal impact on the flow of the clinical procedure, interstitial (in 
situ) label-free vibrational spectroscopy of tissue to ensure biopsy samples are collected in a location containing 
densities of cancer cells sufficiently high for reliable diagnosis. Despite the richer molecular information content 
associated with FP region, the HWN region was chosen since it allowed the use of a practical fiberoptic configura-
tion that satisfies the stringent miniaturization constraints required for direct integration with a commercial brain 
biopsy needle. In particular, fiberoptic FP probes typically require interference filters to be positioned close to the 
distal end of the fibers to minimize detection of the background due to elastic (Rayleigh) light scattering in the 
tissue and the contribution of Raman-active molecules from the optical fibers36. This is crucial for intraoperative 
applications because of the rarity of inelastic scattering events such that real time (<1 s) detection can only be 
achieved in situations where the contribution of non tissue-specific backgrounds is minimal. However, the filter 
constraint is relaxed in the HWN region because of the low silica Raman activity in the fibers and the large shift 
between the excitation and the detection spectral bands that markedly reduces the elastic scattering contribution 
to the detected signal.
A core needle biopsy consists of an outer cannula and an inner cannula, both with rectangular windows 
through which a tissue sample can be aspired and cut following rapid relative rotation of the two cannulas. 
Optical measurement capability was integrated into a commercial brain needle biopsy (Medtronic, Inc) by attach-
ing optical fibers around the periphery of the outer cannula (Fig. 1). The distal tips of these fibers were polished 
at an angle for side illumination and positioned to ensure that measurements are made in the middle (along the 
www.nature.com/scientificreports/
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main axis) of the biopsy window. The collected tissue spectra correspond spatially to the physical tissue biopsy 
volume once the operator rotates the needle by 180° prior to sample collection. A biocompatible polymer cover 
with low Raman signal (no carbon-hydrogen bonds) protected the optical fibers. For initial proof-of-principle 
in vivo measurements, one of the optical fibers was connected to a 671 nm diode laser for excitation and the 
reemitted light was detected through the same fiber by a spectrometer (ANDOR Technologies, Inc). Instrument 
control and data acquisition were achieved using a custom LabView software (National Instruments, Inc), allow-
ing the Raman spectra to be visualized in real time as they are collected. Each spectrum covered the range 2600–
3800 cm−1 at a spectral resolution ∼1.8.cm−1. More details relating to the design and fabrication of the interstitial 
optical system are provided in the Methods section.
Measurements were made to insure that the optical 
needle biopsy system can retrieve reliable HWN Raman spectra in brain tissue. Initially, ex vivo spectra were 
acquired on a calf brain to evaluate the ability of the system to distinguish between white and gray matter. The tip 
of the excitation/detection fiber was placed in contact with either white or gray matter at 20 different locations 
and the mean spectra were computed for each tissue type (Fig. 2b). Compared with gray matter (blue spectrum), 
the white matter spectrum (in red) demonstrates larger contributions from lipids (2845 cm−1) and a lower contri-
bution from proteins and nucleic acids (2930 cm−1), in agreement with the literature26,34.
An experiment was then conducted in two pig brains in situ to demonstrate technical feasibility of deep 
brain spectroscopy. Computed tomography angiography (CTA) of the animal head was done before the proce-
dure to determine a safe trajectory for the needle in order to avoid major blood vessels, and a frameless system 
(Medtronic, Inc.) was used to secure the needle on the cranium and to ensure a straight trajectory into the brain 
is followed (Fig. 2a). After intracranial insertion of the needle through a burr hole, Raman measurements were 
made at several locations (21 in total) along its trajectory. After each measurement, the needle was rotated by 
180° and a tissue sample was collected for histopathology analysis. Of the 21 brain samples, 9 were heteroge-
neous (containing both white matter and cortex), 8 contained only cortex, 1 contained only white matter and 3 
Figure 1. Schematic representation of the optical core needle biopsy, with a magnified view of the tip showing 
the biopsy window and the beveled optical fibers used for illumination and detection. The fibers are located 
opposite to the biopsy window and the needle is rotated by exactly 180° to collect a tissue sample spatially  
co-localized with a spectral measurement. Figure produced by Dariush Bagheri.
Figure 2. RS measurements in normal brain. (a) Schematic of the in vivo acquisition steps: 1) needle insertion 
along the planned trajectory, 2) RS collection, 3) 180° rotation of the needle, and 4) tissue collection. (b) In vivo 
Raman spectra averaged over all measurements (n = 11) and compared with ex vivo spectra for white matter 
and cortex.
www.nature.com/scientificreports/
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contained other brain structures such as blood vessels. The mean spectrum associated with samples containing 
cortex and/or white matter (n = 18) was computed (Fig. 2b). The resulting in situ brain spectrum is consistent 
with the ex vivo data, showing characteristic spectral features of cerebral tissue, mostly from proteins (2930 cm−1) 
and lipids (2845 to 2885 cm−1). This experiment confirmed that the device can be easily and safely inserted into 
the brain and generate Raman spectra with low acquisition time (Table S2) and minimal disruption of a standard 
biopsy procedure.
A clinical 
study was conducted in 19 grade 2–4 glioma patients to determine whether or not HWN RS can differentiate 
normal brain from tissue containing cancer cells. The system setup and clinical validation details can be found 
in the Methods section, together with further details relating to the intraoperative use of the hand-held contact 
probe that we have reported previously in which the FP rather than the HWN region was used23. Ten to fifteen 
sites were interrogated in each patient for a total of 280 measurements (Fig. 3a). Tissue was sampled at each site 
for blinded histopathological analysis to estimate the percentage of cancer cells within the interrogated region 
based on Hematoxylin & Eosin (H&E) staining (see Methods for details). Information relating to sample size and 
patient histological diagnosis information is given in Table 1.
In total, 105 measurements were made on normal brain (no cancer cells present), 51 in infiltrated brain (≤60% 
cancer cells present), and 124 in dense cancer (>60% cancer cells present). In the case of infiltrated brain tissue, 
the percentage of cancer cells in the samples ranged from only a few infiltrative cells (<5%) to 60%. The mean 
spectra for normal brain, infiltrated brain and dense cancer for all patients were computed (Fig. 3c). Sample his-
topathology images for the three groups are provided showing H&E images of dense cancer, infiltrated brain and 
normal brain (Fig. 3c). The in vivo spectra for normal brain tissue acquired with the hand-held HWN RS probe 
are consistent with the spectra acquired in calf and swine brain using the optical biopsy needle.
Identified 
prominent peaks (Fig. 3b) are associated mainly with CH2 symmetric and asymmetric stretches of lipids and 
proteins (2845–2885 cm−1), symmetric CH3 stretch due primarily to proteins (2930 cm−1) and the OH stretch-
ing from water molecules (at 3450 cm−1). The peak at 3240 cm−1 comes from the sapphire of the tip lens in the 
hand-held contact probe. It was not observed in the spectra acquired with the optical biopsy needle since no lens 
was used in the design of that instrument. The most significant biochemical differences between dense cancer and 
normal brain were assessed based on a two-sided t-test of the individual RS peaks. Tissue bands associated with 
some biomolecules are dominant either in normal brain or dense cancer (Table S1). Particularly, peaks associated 
mostly with the presence of proteins (2930 cm−1) were found to be higher for dense cancer tissue. Figure 4a shows 
box plots of the ratio of inelastic scattering intensity at 2930 and 2845 cm−1, a metric used to quantify the relative 
fraction of proteins and lipids. These data demonstrate an increase in the protein/lipid ratio for dense cancer 
compared to normal brain samples, consistent with findings by Ji et al. in ex vivo brain samples using stimulated 
Figure 3. (a) Schematic depiction of in vivo RS measurements taken in the surgical cavity during glioma 
resection using the handheld contact probe in dense cancer (red), infiltrated brain (yellow) and surrounding 
normal brain. (b) In vivo high wavenumber Raman spectra of dense cancer, infiltrated brain and normal brain, 
averaged over all samples. (c) Representative H&E-stained micrographs for each tissue type.
www.nature.com/scientificreports/
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RS27. However, when compared with that of normal brain, the protein/lipid ratio in infiltrated samples does not 
show significant differences.
While individual measures such as peak ratios can provide valuable biochemical information for tissue differ-
entiation, only multivariate approaches are able to fully utilize the spectrally distributed HWN RS information. 
Classification of the data was therefore performed using a support vector machine (SVM) algorithm and its 
performance was preliminarily evaluated using a leave-one-out cross-validation (LOOCV) approach, with the 
histopathological assessment as ground truth. The most important clinical goal here is to follow needle trajec-
tory planning using conventional imaging methods by a confirmation that the needle has reached a location 
associated with a brain area containing cancer cells in proportions relative to normal brain than enable reliable 
diagnosis. Here, the tumor cells density that was deemed sufficient was set at 60% based on neuropathologist 
experience (more details in the Methods section). Therefore, the unmet clinical need to reduce non-diagnostic 
biopsies can be addressed if the proposed technique can detect – and thus target for collection – cancer tissue 
associated with a large enough density of cancer cells. For classification purposes the 280 samples were divided 
into two categories. The so-called non-diagnostic category contains samples that should not have been collected 
because they are either associated with normal brain or with infiltrated tissue containing less than 60% of cancer 
cells. The second category, labeled dense cancer is associated with samples with >60% cancer cells and that should 
have been collected for diagnostic purposes. Based on multivariate classification, dense cancer samples could be 
distinguished from non-diagnostic samples with an accuracy of 84%, a sensitivity of 80%, a specificity of 90% and 
a receiver-operating-characteristic ROC curve with an area-under-the-curve (AUC) of 0.9 (Fig. 4b).
Discussion
There is a critical need in modern medicine for new molecular targeting techniques that can be seamlessly inte-
grated with standard biopsy procedures to increase diagnostic yield and insure optimal treatment planning. Here, 
using brain cancer as a model, we developed a real time interstitial tissue characterization technique acquiring 
molecular vibrational spectroscopy measurements at the distal end of a commercial biopsy needle to ensure 
co-location with biopsy sample collection. A detailed proof of principle was presented, initially demonstrating 
n patients n samples (n normals)
Age (year), median (range) 54 (31–77)
WHO grade
Grade 2
Astrocytoma 2 20 (6)
Oligodendroma 1 22 (4)
Grade 3
Oligodendroglioma 2 35 (16)
Astrocytoma 1 15 (8)
Grade 4






Table 1. Patient histological diagnosis, indicating tumor grade and type as well as sample size information.
Figure 4. (a) Boxplots of the ratio of the lipid and protein bands (2930 cm−1/2845 cm−1) for normal brain, 
infiltrated brain and dense cancer tissue in glioma patients. (b) Receiver operating characteristic (ROC) curve 
computed using the SVM algorithm and leave-one-out cross-validation. The indicated point at the minimal 
distance from the upper-left corner of the ROC curve was chosen for calculating the sensitivity and specificity 
values.
www.nature.com/scientificreports/
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the new optical biopsy needle can detect subtle molecular differences between white matter and cortex ex vivo in 
calf brain, followed by a technical feasibility of in vivo spectroscopy and tissue sampling deep into the brain in a 
swine model. Then, using a different instrument (an intraoperative handheld probe) during 19 human neurosur-
gical resection procedures, we provided evidence that the same molecular contrast detected by the new system 
could be used to locate cancer tissue in vivo (sensitivity and specificity >80%) to target biopsy location. Because 
the optical fibres are integrated with a commercial biopsy needle with measurements taking <2 s, the new optical 
biopsy needle could be used as a synergistic complement to standard of care brain biopsy procedures with mini-
mal disruption of the clinical workflow. Less constraining strategies, in which placement of miniaturized optical 
probes within the outer cannula of the needle alternates with placement of the inner cannula for tissue collection, 
were not considered because of the potential to add significant time to the clinical workflow and so limit the 
number of measurements that can be made. Clinical translation of the proposed technique could eliminate the 
need for inserting a separate optical probe and collecting multiple samples as well as reduce repeat brain needle 
biopsy procedures by insuring only one biopsy sample is harvested that contains a sufficient density of cancer cells 
for diagnosis. Incidentally this could allow optimal treatment planning as well as lead to a reduction of the risks to 
patient health caused by haemorrhages and infections during needle insertion and tissue collection.
A crucial component of future in-human clinical studies with the new system will be the development of 
robust statistical models insuring cancer cells detection with supervised multivariate techniques can be achieved 
in vivo during a procedure37. However, this requires the acquisition of large patient datasets, which could be chal-
lenging in terms of achieving statistical significance and capturing the full heterogeneity associated with tumors 
and normal brain, given only a few biopsy samples are normally collected per biopsy procedure37. An indirect 
but nevertheless valid approach is to train the statistical model on vibrational spectroscopy data acquired in 
vivo during surgical resection, since multiple measurements/samples can then be acquired for each patient. This 
is precisely what was done here using the intraoperative handheld probe23,24 during open-cranium surgery. A 
critical factor insuring the validity of this approach will be to take into account any differences in the instrument 
spectral-response function to allow the algorithm trained with the intraoperative handheld probe to be directly 
applied to data acquired with the optical biopsy needle. In the present study the observed differences between 
brain spectra acquired with the optical needle (Fig. 2) and the intraoperative probe (Fig. 3) are attributable to 
differences in the noise level, and the contribution from the Raman-active molecules in the contact probe lens. 
The photonic noise is larger in the optical needle spectra, since it uses only a single optical fibre with a smaller 
diameter, whereas the contact probe uses 7 collection fibres of larger core diameter (Table S2). Additionally, 
the effective excitation power is lower by a factor of ∼5 in the optical needle. These signal discrepancies will 
be offset by using all 12 needle fibers simultaneously at comparable excitation powers and signal integration 
times, and applying separately-measured corrections for the different spectral-response functions. Importantly, 
the statistical models will be made using data where the spectral region around the Raman peak associated with 
the lens material is truncated to ensure exact correspondence between data acquired with the different probes. 
In this proof-of-concept study, a single fiber (out of 12 that were available) was used for excitation and detection. 
However, several fibers could have been use in spatial offset mode38–40 to increase detection volume and pene-
tration depth. In the case of cancer cells detection, considering that the signal of interest is very weak, there is a 
compromise between detection volume and signal to noise ratio. Decreasing detection volume might produce a 
better sensitivity for detection, but only if the signal to noise ratio remains unchanged. This translates to a higher 
laser power or acquisition time, so less clinical practicality. An interesting study would be to determine the opti-
mal combination of detection volume, laser power and integration time to lead the best sensitivity for a specific 
application.
The results of the present experiments set the stage for a clinical study using the optical biopsy needle to pro-
vide live tissue classification during brain needle biopsy procedures. However, brain tissue sampling is among 
the most accurate biopsy procedures, in large part due to the use of stereotactic approaches and advanced 
image-guided techniques. Online molecular characterization would be even more important for diagnostic of 
disease in other organ systems where conventional imaging techniques are less specific and guidance techniques 
used less accurate41. Oncology applications with high levels of misdiagnosis at biopsy include prostate and lung, 
but also other organ sites such as breast and colon2,10–12,42–45. Because of all the tissue processing steps needed 
before microscopic histopathological analyses, the presence of cancer in the biopsy cores is only confirmed after 
a few days, and up to several weeks if a molecular analysis is required. In cases of uncertain diagnosis repeat 
biopsies are required, adding significant delay before diagnosis can be obtained and a treatment chosen, and 
increasing risk for the patient. The new technique also shows great potential in interventional medicine applica-
tions beyond biopsies to optimize targeted treatment methods such as in laser-induced thermotherapy (LIIT)46, 
brachytherapy47,48 or therapeutics injection of viruses into tumors.
Although clinical translation of the new technique for organ systems other than brain has the potential to 
significantly reduce instances of misdiagnosis, it will require significant efforts to insure the optical technology is 
integrated into clinical practice in a manner that is minimally disruptive to the standard workflow. This will not 
only include developing the vibrational spectroscopy technique to fit with instrumentation used as the standard 
of care (e.g., bronchoscope, laparoscope) but will also require the development of statistical models for each 
pathology of interest. Here, we have presented a proof of principle demonstrating clinical integration of high 
wavenumber Raman spectroscopy in brain needle biopsy procedures. Although more challenging from an engi-
neering perspective, developing optical biopsy needles detecting in the fingerprint region would lend even more 
molecular information, with incidental increases in sensitivity and specificity for cancer detection23,24,28 and thus 
a potential for even more precise targeting for biopsy sample collection.
www.nature.com/scientificreports/
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The biopsy needle probe comprises 12 low-hy-
droxyl fibers of 105 μm core diameter, 150 μm outer diameter and 0.22 NA (numerical aperture) for excitation 
and collection, distributed around the needle to provide 200° azimuthal angular coverage. Since total internal 
reflection is used to create a side viewing fiber, an air interface is required at the angle polished end of the fiber. 
The fiber tips were polished at a 37° angle to ensure total internal reflection. 12 thin polymer tubes (170 μm inner 
diameter, 355 μm outer diameter) were heat fused together, and each of their distal ends were heat fused close to 
ensure no liquid infiltration. The 12 tubes were placed around the external cannula of the needle, on the 200° not 
covered by the biopsy window. The fibers were inserted in each tube one at a time so that the angled end is aligned 
to the center of the needle biopsy window, and rotated to the proper orientation to ensure the fiber emission and 
collection cone was normal (outward) to the BNB needle. This is repeated for all 12 fibers. The tubes around the 
fibers create the air interface at the angled ends, required for total internal reflection. Epoxy was used to close the 
proximal tube ends to prevent any liquid infiltration. A thin wall heat shrink was placed over both ends of the 
tubes/fibers to hold them in place on the needle. The heat shrink was not placed over the angled portion of the 
fibers so no Raman signature of the heat shrink would be collected. The fibers at the proximal end of the needle 
were placed in a 1 m long nylon protective tube (1.55 mm inner diameter, 1.8 mm outer diameter) to a breakout 
section which each fiber is protected individually by a 0.75 m long nylon protective tube (1.55 mm inner diameter, 
1.8 mm outer diameter). The fibers were terminated individually with FC/PC connectors.
For the current proof-of-principle experiments, a single fiber of the needle 
probe was used. A 785 nm dichroic beam splitter (Semrock, Inc) is used to separate the illumination and detection 
light and the light collection used a laser-line band-pass filter (Ravg > 97% from 705–900 nm, Semrock, Inc) and a 
long-pass filter (Tavg > 93% from 812.9–1200 nm, Semrock, Inc), together with collimating lenses (Thorlabs, Inc). 
A 750 mW, 671 nm spectrum stabilized near-infrared laser (Laser Quantum, Inc) with adjustable power is used 
for Raman excitation. The collection path is connected to a spectrograph comprising a diffraction grating coupled 
to a high-resolution charge-coupled-device (CCD) camera (ANDOR Technology, Inc.). A fresh normal calf brain 
was used for the ex vivo proof-of-concept study, since this has a Raman signature and background similar to that 
of human brain tissue24. Contact Raman spectral measurements were made on different locations, and tissues 
were labeled white matter or gray matter by visual assessment. An imaging sequence comprises a background 
acquisition (laser turned off) and acquisition of 3 Raman spectra at the same location, with integration times of 
0.5–2 s for each measurement. A fixed laser power of 10 mW was used to avoid damaging the polymer tubing 
from blood heating around the fiber tips. All ambient sources of light were turned off during acquisitions.
In vivo The in vivo animal study was approved by the institutional Ethics 
Review Board (CHUM Research Center, Montreal, Canada), and all methods were performed in accordance with 
the relevant guidelines and regulations. Two adult 20–30 kg pigs were anaesthetised using a standard injection 
and gas inhalation procedure. Raman measurements were acquired using two different procedures in each animal 
(through a burr hole and following craniotomy) to access the brain with the RS biopsy needle. In both cases an 
X-ray contrast agent (Visipaque 370, 15 ml) was first injected via a catheter placed in the carotid artery, and CT 
difference angiography was performed to highlight intracranial blood vessels. For the first animal, the burr hole 
location was selected and a trajectory for the needle was chosen to achieve maximum depth and avoid intercepting 
major blood vessels during needle insertion through the dura. The Navigus frameless system (Medtronic, Inc.) was 
installed on the skull and the biopsy needle was aligned to its calculated trajectory. The needle was inserted until it 
reached the target location using navigational software (iGuide, Siemens Healthcare, Inc.). Data acquisition con-
sisted of a 0.5 s background measurement (laser off) and 3 Raman spectra measurements with 0.5 s acquisition time 
at the target location. The probe was then rotated 180° and a tissue sample (typically 1 cm long and ∼1–2 mm wide) 
was extracted by opening the biopsy window, aspirating tissue into the inner cannula and cutting the sample by 
rotating the inner cannula. These acquisition steps were repeated at different insertion depths (n = 8) while pulling 
out the needle along its trajectory. The samples were fixed in formalin for subsequent histopathologic assessment 
to distinguish gray and white matter. In the second pig, a craniotomy was performed to provide direct access to 
the brain. Since finding locations of white and gray matter is difficult based on a single trajectory of the needle, this 
approach was used on the second animal to access different areas of the brain more easily. The needle was inserted 
manually into the brain, and the RS and biopsy sequence was repeated for various locations and depths (n = 13). 
The total time for optical measurements and tissue sample collection was ∼15–20 min for each animal. The meas-
ured spectra were processed as follows: 1) averaging of the 3 spectra at each location and background subtraction 
(measurement with the laser off), 2) correction for the instrument response using measurements of a calibrated 
halogen white light (National Institute of Standards and Technology, Maryland, USA), 3) removal of intrinsic tissue 
fluorescence using an iterative polynomial fit49 and 4) standard normal variate (SNV) normalization. Spectra from 
samples found on pathology to include other tissues such as blood vessel and choroid plexus were excluded from 
the analysis, so that 18 spectra were kept for the analysis and their average was computed.
In vivo validation was per-
formed with a contact intraoperative probe that was previously used to demonstrate that fingerprint RS is able 
to distinguish normal brain tissue from tissue containing cancer cells23,24. In order to use the same spectrometer 
(same spectral range in nanometers), a 671 nm laser was employed with this probe to measure higher frequency 
shifts. Slight modifications were also made to the design of the intraoperative probe previously used to make it 
capable of both fingerprint and high wavenumber RS. This modified probe has a 2.1 mm outer diameter con-
taining 7 low-hydroxyl, 300 μm core fibers for light collection distributed around a central 272 μm core source 
fiber. The reemitted signal passes through a ring-shaped notch filter to remove elastically backscattered light and 
www.nature.com/scientificreports/
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light scattered from the lens surface. The band-pass filter used in front of the excitation fiber was replaced with 
an in-line short-pass filter to allow the 671 nm excitation. A custom sapphire 2-component lens was used at the 
tip of the probe to overlap the excitation and detection volumes. The illumination and detection instruments 
are the same as for the animal study, previously described in detail. The 7 collection fibers were connected to the 
spectrometer through a single custom-built SMA connector. The laser spot size of the probe (tissue excitation 
area) of the handheld probe had a diameter of 0.5 mm and a field of view associated with a single point of that 
same diameter. Further, light transport simulations in tissue using a Monte Carlo technique demonstrated that 
the sampling depth is ∼ 1mm50. Similar results are expected both for the handheld probe and the optical biopsy 
needle since tissue excitation and detection are spatially co-located.
This study investigated high-wavenumber RS using the mod-
ified handheld contact probe in 19 adult patients undergoing open cranium surgery for grade 2–4 glioma at 
the Montreal Neurological Institute and Hospital, under institutional Ethics Board approval and with informed 
consent. All methods were performed in accordance with the relevant guidelines and regulations. Preoperative 
neurological examination was performed, as well as standard clinical imaging by magnetic resonance (MRI). For 
the intraoperative measurements the system was placed on a surgical cart, brought in the operating room and 
connected to the previously sterilized probe. Purpose-built acquisition software was operated by a member of the 
instrument-development group, while the neurosurgeon handled the probe within the surgical sterile area. The 
surgeon first put the probe in contact with brain tissue in the surgical cavity followed by Raman spectroscopy 
acquisition. The RS sequence comprised a series of single-point spectral acquisitions with step-wise automatic 
laser power adjustment to find a power that optimized the use of the detector’s dynamic range without saturation, 
a background acquisition with the laser turned off, and then collection of 3 Raman spectra. Each spectral meas-
urement required that the neurosurgical microscope light be turned off temporarily to minimize ambient-light 
artefacts24. Following spectral acquisition, the neurosurgeon collected a small biopsy sample (~1.5 mm) at the 
interrogated site, located by the visible indentation of the tissue surface from the probe contact. Biopsy samples 
were fixed in formalin, embedded in paraffin, H&E stained and evaluated using a standard blinded protocol by an 
expert neuropathologist. Using standard clinical practice, atypical cells were identified based on their morpholog-
ical features, including nuclear atypia and nuclear polymorphism and mitotic figures. Each sample was classified 
as either: normal brain (no cancer cells present), infiltrated (presence of cancer cells within non tumoral brain 
parenchyma), or dense cancer. For each infiltrated sample, the pathologist estimated the percentage of cancer 
cells in the sample (number of cancer cells divided by the total number of cells). Samples were rejected if optical 
artifacts were observed in the Raman signal (4 samples), if the CCD saturated during acquisition (3 samples) or if 
the biopsy sample was partitioned, i.e. containing focal area(s) of different tissue types (10 samples).
Processing for RS involves background subtraction, correction for 
the instrument response, the removal of intrinsic tissue fluorescence49 and normalization. Regarding classification, 
classes were chosen based on the clinical application and limitations of brain needle biopsy. The density of cancer 
cells in the sample plays an essential role in obtaining all the components for the integrated diagnosis of gliomas, as 
recommended by the WHO classification of tumors of the central nervous system51. Analysis of samples containing 
a minimum number of tumor cells is required for the identification of biomarkers essential for accurate diagnosis, 
ensuring optimal treatment planning and prognosis for the patient. For example, standard of care for the manage-
ment of patients with glioma includes the detection of the IDH1 R132H point mutation as well as the status of the 
promoter of the MGMT gene for which, as is also the case for DNA sequencing, a minimum percentage of tumoral 
cells is necessary to get reliable and reproducible results52,53. Thus, a threshold of 60% of cancer cells or higher was set 
since it is sufficient to achieve a precise diagnosis, based on neuropathologist experience (MCG). A Support Vector 
Machine (SVM) technique was used for RS tissue classification using 141 features of the spectra, chosen based on 
the p-values computed for the correlation between a particular spectral feature and the tissue type. Therefore, the 
spectral features used were those most correlated with the difference between cancer and normal tissue. The number 
of features was optimized to find the best outcome. Leave-one-out cross-validation (LOOCV) was used to deter-
mine the classification accuracy, sensitivity and specificity, treating all spectra except one as the training data for the 
classifier, with the other spectra as the testing data and repeating this for each spectrum. The sample size (number of 
patients and measurements per patient) was selected with the goal of achieving two-sided 95% normal-based confi-
dence intervals of less than ± 5% for all reported classification results, based on cross-validation.
The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
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